Inspire Medical Systems Secures $14.5M for Neurostim Apnea Treatment

Inspire Medical Systems Secures $14.5M in Series C Financing, Completes Implants in its STAR Pivotal Trial, and Announces Publication of Feasibility

MINNEAPOLIS, MN — May 11, 2012 – Inspire Medical Systems, the leading developer of neurostimulation therapies for the treatment of obstructive sleep apnea (OSA), provided an update today on four important company initiatives:

— Inspire completed a Series C financing round of $14.5 million.

— Inspire completed patient enrollment and device implants in its STAR pivotal trial.

— Inspire announced the publication of its feasibility study results in the May 2012 edition of the Laryngoscope journal.

— Inspire conducted commercial implants in Germany, Italy and The Netherlands.

Inspire has completed a Series C financing round of $14.5 million. The funds will be used to support clinical trial patient follow-up, U.S. regulatory submissions, and expansion of commercial activities in Europe. Participating in this round of financing are new investors, Medtronic and TGap Ventures, and existing investors, including Kleiner Perkins Caufield & Byers, US Venture Partners, Synergy Life Science Partners and GDN Holdings.

Inspire also announced the completion of patient recruitment and device implants in the STAR pivotal trial (Stimulation Therapy for Apnea Reduction). The STAR trial is a multi-center study that is evaluating the safety and effectiveness of Inspire® Upper Airway Stimulation (UAS) therapy in patients with moderate to severe obstructive sleep apnea (OSA).The STAR trial is being conducted at leading medical centers across the United States and Europe. All implanted patients are being closely followed, and the results of this study will be the basis for a Pre-Market Approval (PMA) application to the FDA which is targeted for early 2013.

Additionally, Laryngoscope, the journal of the American Laryngological, Rhinological and Otological Society published in its May issue the results of two earlier clinical trials conducted by Inspire investigators. The publication reported that Inspire® Upper Airway Stimulation (UAS) therapy is safe and efficacious in a select group of patients with moderate to severe OSA who cannot or will not use CPAP as primary treatment. The abstract of the study titled, Implanted upper airway stimulation device for obstructive sleep apnea, is available here.

“Inspire has broadened its investor base, finished enrollment in its STAR pivotal trial, and completed commercial implants in three European countries,” said Dr. Glen Nelson, Chairman of the Board of Inspire Medical Systems. “Achievement of these critical milestones is a testament to the experience and ability of Inspire’s leadership team.”

Inspire previously announced receipt of its CE Mark in 2010, and to date has completed commercial implants in Germany, Italy and The Netherlands. Inspire has a strong European team focused on the broader adoption of Inspire therapy in Europe.

“Obstructive Sleep Apnea is a prevalent disorder affecting over 15 million people in The United States alone. A substantial number of these patients are unable to achieve consistent benefit from conservative therapies. The swift enrollment of our STAR pivotal trial demonstrates the significant interest that patients have in Inspire therapy. It also reflects the strong commitment our physician investigator group has made to develop this promising therapy,” said Tim Herbert, President and CEO of Inspire Medical Systems. “Our focus now is to gain regulatory approvals and to secure reimbursement mechanisms so that this patient group will have access to our breakthrough technology.”